Aroa Biosurgery Limited (ASX:ARX)
Australia
· Delayed Price · Currency is AUD 0.5900
+0.0150 (2.61%)
Jul 4, 2025, 4:10 PM AEST
Aroa Biosurgery Income Statement
Financials in millions NZD. Fiscal year is April - March.
Millions NZD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2018 - 2020 |
| 84.7 | 69.07 | 63.36 | 39.68 | 22.34 | Upgrade
| |
Revenue Growth (YoY) | 22.63% | 9.01% | 59.68% | 77.60% | -10.90% | Upgrade
|
Cost of Revenue | 12.08 | 10.09 | 9.88 | 9.38 | 6.82 | Upgrade
|
Gross Profit | 72.61 | 58.97 | 53.48 | 30.3 | 15.52 | Upgrade
|
Selling, General & Admin | 67.05 | 62.15 | 47.71 | 30.71 | 21.76 | Upgrade
|
Research & Development | 9.57 | 9.16 | 10.61 | 8.35 | 6.43 | Upgrade
|
Other Operating Expenses | -1.08 | -1.66 | -1.73 | -1.12 | -2.68 | Upgrade
|
Operating Expenses | 75.53 | 69.64 | 56.59 | 37.95 | 25.5 | Upgrade
|
Operating Income | -2.92 | -10.67 | -3.11 | -7.64 | -9.98 | Upgrade
|
Interest Expense | -0.48 | -0.49 | -0.38 | -1.15 | -1.91 | Upgrade
|
Interest & Investment Income | 1.06 | 1.8 | 1.32 | 0.4 | 0.15 | Upgrade
|
Currency Exchange Gain (Loss) | -0.9 | -1.05 | 1.8 | 0.13 | 0.65 | Upgrade
|
Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0 | -0 | Upgrade
|
EBT Excluding Unusual Items | -3.25 | -10.43 | -0.38 | -8.26 | -11.09 | Upgrade
|
Other Unusual Items | - | - | - | - | -8.01 | Upgrade
|
Pretax Income | -3.25 | -10.43 | -0.38 | -8.26 | -19.1 | Upgrade
|
Income Tax Expense | 0.56 | 0.2 | 0.01 | 0.13 | 0.11 | Upgrade
|
Net Income | -3.81 | -10.63 | -0.4 | -8.39 | -19.21 | Upgrade
|
Net Income to Common | -3.81 | -10.63 | -0.4 | -8.39 | -19.21 | Upgrade
|
Shares Outstanding (Basic) | 345 | 344 | 343 | 342 | 300 | Upgrade
|
Shares Outstanding (Diluted) | 345 | 344 | 343 | 342 | 300 | Upgrade
|
Shares Change (YoY) | 0.31% | 0.27% | 0.22% | 13.90% | 10620.95% | Upgrade
|
EPS (Basic) | -0.01 | -0.03 | -0.00 | -0.02 | -0.06 | Upgrade
|
EPS (Diluted) | -0.01 | -0.03 | -0.00 | -0.02 | -0.06 | Upgrade
|
Free Cash Flow | -4.88 | -10.9 | -9.8 | -15.98 | -6.27 | Upgrade
|
Free Cash Flow Per Share | -0.01 | -0.03 | -0.03 | -0.05 | -0.02 | Upgrade
|
Gross Margin | 85.73% | 85.39% | 84.40% | 76.37% | 69.48% | Upgrade
|
Operating Margin | -3.45% | -15.45% | -4.91% | -19.26% | -44.66% | Upgrade
|
Profit Margin | -4.50% | -15.39% | -0.63% | -21.13% | -85.98% | Upgrade
|
Free Cash Flow Margin | -5.76% | -15.78% | -15.47% | -40.27% | -28.07% | Upgrade
|
EBITDA | 0.26 | -7.4 | -0.08 | -5.29 | -7.67 | Upgrade
|
EBITDA Margin | 0.30% | -10.71% | -0.13% | -13.32% | -34.33% | Upgrade
|
D&A For EBITDA | 3.17 | 3.28 | 3.03 | 2.36 | 2.31 | Upgrade
|
EBIT | -2.92 | -10.67 | -3.11 | -7.64 | -9.98 | Upgrade
|
EBIT Margin | -3.45% | -15.45% | -4.91% | -19.26% | -44.66% | Upgrade
|
Updated Nov 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.